These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28129808)

  • 41. Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening.
    Ren CL; Fink AK; Petren K; Borowitz DS; McColley SA; Sanders DB; Rosenfeld M; Marshall BC
    Pediatrics; 2015 Jun; 135(6):e1386-92. PubMed ID: 25963008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnosis of cystic fibrosis in the kindred of an infant with CFTR-related metabolic syndrome: importance of follow-up that includes monitoring sweat chloride concentrations over time.
    Williams SN; Nussbaum E; Chin TW; Do PC; Singh KE; Randhawa I
    Pediatr Pulmonol; 2014 Mar; 49(3):E103-8. PubMed ID: 24535988
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
    Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
    J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cystic fibrosis screen positive inconclusive diagnosis (CFSPID): Experience in Tuscany, Italy.
    Terlizzi V; Mergni G; Buzzetti R; Centrone C; Zavataro L; Braggion C
    J Cyst Fibros; 2019 Jul; 18(4):484-490. PubMed ID: 31005549
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
    Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
    J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.
    ; Borowitz D; Parad RB; Sharp JK; Sabadosa KA; Robinson KA; Rock MJ; Farrell PM; Sontag MK; Rosenfeld M; Davis SD; Marshall BC; Accurso FJ
    J Pediatr; 2009 Dec; 155(6 Suppl):S106-16. PubMed ID: 19914443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Newborn blood spot screening for cystic fibrosis with a four-step screening strategy in the Netherlands.
    Dankert-Roelse JE; Bouva MJ; Jakobs BS; Janssens HM; de Winter-de Groot KM; Schönbeck Y; Gille JJP; Gulmans VAM; Verschoof-Puite RK; Schielen PCJI; Verkerk PH
    J Cyst Fibros; 2019 Jan; 18(1):54-63. PubMed ID: 30146269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
    Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
    Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The implications and management of cystic fibrosis screen positive, inconclusive diagnosis patients.
    Krishnananthan T; Pao C
    Paediatr Respir Rev; 2019 Aug; 31():21-24. PubMed ID: 31153793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thirty-years of screening for cystic fibrosis in East Anglia.
    Calvin J; Hogg SL; McShane D; McAuley SA; Iles R; Ross-Russell R; MacLean FM; Heeley ME; Heeley AF;
    Arch Dis Child; 2012 Dec; 97(12):1043-7. PubMed ID: 23076339
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Guidelines for the clinical management and follow-up of infants with inconclusive cystic fibrosis diagnosis through newborn screening.
    Sermet-Gaudelus I; Brouard J; Audrézet MP; Couderc Kohen L; Weiss L; Wizla N; Vrielynck S; LLerena K; Le Bourgeois M; Deneuville E; Remus N; Nguyen-Khoa T; Raynal C; Roussey M; Girodon E
    Arch Pediatr; 2017 Dec; 24(12):e1-e14. PubMed ID: 29174009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic problems in cystic fibrosis - specific characteristics of a group of infants and young children diagnosed positive through neonatal screening, in whom cystic fibrosis had not been diagnosed.
    Woś H; Sankiewicz-Szkółka M; Więcek S; Kordys-Darmolińska B; Grzybowska-Chlebowczyk U; Kniażewska M
    Dev Period Med; 2015; 19(1):25-31. PubMed ID: 26003067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonclassic cystic fibrosis and CFTR-related diseases.
    Boyle MP
    Curr Opin Pulm Med; 2003 Nov; 9(6):498-503. PubMed ID: 14534402
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Practice variation of genetic counselor engagement in the cystic fibrosis newborn screen-positive diagnostic resolution process.
    Langfelder-Schwind E; Raraigh KS; Parad RB
    J Genet Couns; 2019 Dec; 28(6):1178-1188. PubMed ID: 31550062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recommendations for the classification of diseases as CFTR-related disorders.
    Bombieri C; Claustres M; De Boeck K; Derichs N; Dodge J; Girodon E; Sermet I; Schwarz M; Tzetis M; Wilschanski M; Bareil C; Bilton D; Castellani C; Cuppens H; Cutting GR; Drevínek P; Farrell P; Elborn JS; Jarvi K; Kerem B; Kerem E; Knowles M; Macek M; Munck A; Radojkovic D; Seia M; Sheppard DN; Southern KW; Stuhrmann M; Tullis E; Zielenski J; Pignatti PF; Ferec C
    J Cyst Fibros; 2011 Jun; 10 Suppl 2():S86-102. PubMed ID: 21658649
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis.
    Mayell SJ; Munck A; Craig JV; Sermet I; Brownlee KG; Schwarz MJ; Castellani C; Southern KW;
    J Cyst Fibros; 2009 Jan; 8(1):71-8. PubMed ID: 18957277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A false positive newborn screening result due to a complex allele carrying two frequent CF-causing variants.
    Bergougnoux A; Boureau-Wirth A; Rouzier C; Altieri JP; Verneau F; Larrieu L; Koenig M; Claustres M; Raynal C
    J Cyst Fibros; 2016 May; 15(3):309-12. PubMed ID: 27117206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does cystic fibrosis neonatal screening detect atypical CF forms? Extended genetic characterization and 4-year clinical follow-up.
    Narzi L; Ferraguti G; Stamato A; Narzi F; Valentini SB; Lelli A; Delaroche I; Lucarelli M; Strom R; Quattrucci S
    Clin Genet; 2007 Jul; 72(1):39-46. PubMed ID: 17594398
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neonatal cystic fibrosis screening: Analysis and differences in immunoreactive trypsin levels in newborns with a positive screen.
    Arrudi-Moreno M; García-Romero R; Samper-Villagrasa P; Sánchez-Malo MJ; Martin-de-Vicente C
    An Pediatr (Engl Ed); 2021 Jul; 95(1):11-17. PubMed ID: 34140271
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cystic Fibrosis Diagnosis and Newborn Screening.
    Rosenfeld M; Sontag MK; Ren CL
    Pediatr Clin North Am; 2016 Aug; 63(4):599-615. PubMed ID: 27469178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.